Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China · Delayed Price · Currency is CNY 9.80
-0.08 (-0.81%)
Jun 11, 2026, 2:05 PM CST
SHE:002900 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 730.78 | 706.97 | 1,071 | 1,153 | 1,008 | 910.39 |
Other Revenue | 82.45 | 82.45 | 61.64 | 34.09 | 20.27 | 35.41 |
| 813.23 | 789.42 | 1,132 | 1,187 | 1,028 | 945.8 | |
Revenue Growth (YoY) | -25.44% | -30.29% | -4.58% | 15.40% | 8.73% | -29.36% |
Cost of Revenue | 550.31 | 530.78 | 553.88 | 475.55 | 360.34 | 312.86 |
Gross Profit | 262.92 | 258.65 | 578.6 | 711.23 | 668.08 | 632.94 |
Selling, General & Admin | 489.18 | 487.94 | 432.05 | 598.15 | 594.6 | 667.1 |
Research & Development | 88 | 93.16 | 105.22 | 112.81 | 89.27 | 99.92 |
Other Operating Expenses | 13.74 | 8.45 | 7.39 | 11.1 | 15.53 | 14.14 |
Operating Expenses | 589.7 | 586.94 | 545.88 | 719.2 | 699.98 | 782.97 |
Operating Income | -326.79 | -328.29 | 32.72 | -7.97 | -31.91 | -150.03 |
Interest Expense | -26.38 | -26.47 | -31.32 | -22.89 | -22.62 | -13.8 |
Interest & Investment Income | 29.76 | 29.15 | 55.45 | 70.54 | 74.24 | 609.35 |
Currency Exchange Gain (Loss) | 0.25 | 0.25 | 0.51 | 0.14 | 1.57 | -0.02 |
Other Non Operating Income (Expenses) | 1.18 | 0.69 | 3.97 | -0.26 | -1.06 | -0.37 |
EBT Excluding Unusual Items | -321.98 | -324.67 | 61.34 | 39.56 | 20.22 | 445.12 |
Impairment of Goodwill | -0.5 | -0.5 | - | - | - | - |
Gain (Loss) on Sale of Investments | -11.28 | -11.31 | -14.64 | 13.37 | 13.87 | -5.13 |
Gain (Loss) on Sale of Assets | -0.86 | -0.52 | 0.19 | -2.61 | -13.31 | -1.92 |
Asset Writedown | -20.65 | -31.09 | -0 | -0 | -2.91 | -0.68 |
Legal Settlements | 0.19 | 0.19 | - | - | - | - |
Other Unusual Items | 30.32 | 14.87 | 13.11 | 31.06 | 22.2 | 15.45 |
Pretax Income | -324.77 | -353.03 | 60.01 | 81.37 | 40.07 | 452.86 |
Income Tax Expense | -5.26 | -11.47 | 5.03 | 11.3 | 13.57 | 103.18 |
Earnings From Continuing Operations | -319.51 | -341.57 | 54.98 | 70.08 | 26.5 | 349.68 |
Minority Interest in Earnings | 1.67 | 1.94 | 3.7 | 3.58 | 3.71 | 1.27 |
Net Income | -317.84 | -339.63 | 58.68 | 73.66 | 30.21 | 350.95 |
Net Income to Common | -317.84 | -339.63 | 58.68 | 73.66 | 30.21 | 350.95 |
Net Income Growth | - | - | -20.35% | 143.86% | -91.39% | 1096.77% |
Shares Outstanding (Basic) | 325 | 317 | 309 | 307 | 302 | 311 |
Shares Outstanding (Diluted) | 325 | 317 | 309 | 307 | 302 | 311 |
Shares Change (YoY) | 4.78% | 2.78% | 0.61% | 1.61% | -2.74% | -4.68% |
EPS (Basic) | -0.98 | -1.07 | 0.19 | 0.24 | 0.10 | 1.13 |
EPS (Diluted) | -0.98 | -1.07 | 0.19 | 0.24 | 0.10 | 1.13 |
EPS Growth | - | - | -20.83% | 140.00% | -91.15% | 1155.56% |
Free Cash Flow | -308.83 | -283.98 | -315.52 | -263.89 | 55.42 | -86.48 |
Free Cash Flow Per Share | -0.95 | -0.90 | -1.02 | -0.86 | 0.18 | -0.28 |
Dividend Per Share | - | - | 0.200 | 0.200 | 0.100 | 0.320 |
Dividend Growth | - | - | - | 100.00% | -68.75% | 300.00% |
Gross Margin | 32.33% | 32.76% | 51.09% | 59.93% | 64.96% | 66.92% |
Operating Margin | -40.18% | -41.59% | 2.89% | -0.67% | -3.10% | -15.86% |
Profit Margin | -39.08% | -43.02% | 5.18% | 6.21% | 2.94% | 37.11% |
Free Cash Flow Margin | -37.97% | -35.97% | -27.86% | -22.23% | 5.39% | -9.14% |
EBITDA | -186.12 | -195.57 | 133.63 | 90.43 | 65.02 | -60.22 |
EBITDA Margin | -22.89% | -24.77% | 11.80% | 7.62% | 6.32% | -6.37% |
D&A For EBITDA | 140.67 | 132.71 | 100.91 | 98.41 | 96.92 | 89.81 |
EBIT | -326.79 | -328.29 | 32.72 | -7.97 | -31.91 | -150.03 |
EBIT Margin | -40.18% | -41.59% | 2.89% | -0.67% | -3.10% | -15.86% |
Effective Tax Rate | - | - | 8.38% | 13.88% | 33.87% | 22.78% |
Revenue as Reported | 813.23 | 789.42 | 1,132 | 1,187 | 1,028 | 945.8 |
Advertising Expenses | - | 23.27 | 16.62 | 51.46 | 43.24 | 31.69 |